These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 15579515

  • 1. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM, RENAAL Study Group.
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [Abstract] [Full Text] [Related]

  • 2. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
    Rev Invest Clin; 2005 Dec; 57(3):399-405. PubMed ID: 16187699
    [Abstract] [Full Text] [Related]

  • 3. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
    Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
    [Abstract] [Full Text] [Related]

  • 4. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S, Citarella A, Cammarota S, Menditto E, Mantovani LG.
    Clin Exp Hypertens; 2011 May 01; 33(3):174-8. PubMed ID: 21466388
    [Abstract] [Full Text] [Related]

  • 5. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 6. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar 14; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 7. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.
    Diabetes Care; 2003 Mar 14; 26(3):683-7. PubMed ID: 12610022
    [Abstract] [Full Text] [Related]

  • 8. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.
    J Am Soc Nephrol; 2007 May 14; 18(5):1540-6. PubMed ID: 17409317
    [Abstract] [Full Text] [Related]

  • 9. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
    Ugeskr Laeger; 2001 Oct 01; 163(40):5514-9. PubMed ID: 11601117
    [Abstract] [Full Text] [Related]

  • 10. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

  • 11. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ.
    Am J Kidney Dis; 2012 Jan 01; 59(1):75-83. PubMed ID: 22051245
    [Abstract] [Full Text] [Related]

  • 12. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul 01; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.
    Diabetes Care; 2006 Oct 01; 29(10):2210-7. PubMed ID: 17003295
    [Abstract] [Full Text] [Related]

  • 14. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 01; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 15. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
    Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.
    Diabetes Care; 2008 Mar 01; 31(3):445-7. PubMed ID: 18070995
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
    Ravera M, Re M, Vettoretti S.
    J Am Soc Nephrol; 2006 Apr 01; 17(4 Suppl 2):S44-8. PubMed ID: 16565246
    [Abstract] [Full Text] [Related]

  • 17. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B, Gleim G, Panish J.
    Curr Med Res Opin; 2004 Dec 01; 20(12):1909-17. PubMed ID: 15701209
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R, Faraone R, Ruggenent P, Remuzzi G.
    J Nephrol; 2002 Dec 01; 15(4):428-30. PubMed ID: 12243375
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
    Stafylas PC, Sarafidis PA, Lasaridis AN, Tsakni E, Niakas DA, Dombros NV, Grekas DM, Bakris GL.
    J Nephrol; 2007 Dec 01; 20(6):703-15. PubMed ID: 18046673
    [Abstract] [Full Text] [Related]

  • 20. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP.
    J Am Soc Nephrol; 2007 Jun 01; 18(6):1889-98. PubMed ID: 17494885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.